241 related articles for article (PubMed ID: 31872284)
1. NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma.
Ma X; Qiu Y; Zhu L; Zhao Y; Lin Y; Ma D; Qin Z; Sun C; Shen X; Li T; Han L
J Mol Med (Berl); 2020 Feb; 98(2):221-232. PubMed ID: 31872284
[TBL] [Abstract][Full Text] [Related]
2. Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway.
Guo XX; Li XP; Zhou P; Li DY; Lyu XT; Chen Y; Lyu YW; Tian K; Yuan DZ; Ran JH; Chen DL; Jiang R; Li J
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30384473
[TBL] [Abstract][Full Text] [Related]
3. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
4. The aryl hydrocarbon receptor ligand ITE inhibits cell proliferation and migration and enhances sensitivity to drug-resistance in hepatocellular carcinoma.
Zhang X; He B; Chen E; Lu J; Wang J; Cao H; Li L
J Cell Physiol; 2021 Jan; 236(1):178-192. PubMed ID: 32510618
[TBL] [Abstract][Full Text] [Related]
5. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
7. RBFOX3 Regulates the Chemosensitivity of Cancer Cells to 5-Fluorouracil via the PI3K/AKT, EMT and Cytochrome-C/Caspase Pathways.
Liu T; Wu X; Li Y; Lu W; Zheng F; Zhang C; Long Q; Qiu H; Li Y; Ge Q; Chen M; Yu X; Chen W; Zhang H; Huang W; Luo M; Deng W; Li L
Cell Physiol Biochem; 2018; 46(4):1365-1380. PubMed ID: 29689552
[TBL] [Abstract][Full Text] [Related]
8. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
[TBL] [Abstract][Full Text] [Related]
9. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
10. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
Hou H; Ge C; Sun H; Li H; Li J; Tian H
Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
[TBL] [Abstract][Full Text] [Related]
11. Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathway.
Wu F; Chen WJ; Yan L; Tan GQ; Li WT; Zhu XJ; Ge XC; Liu JW; Wang BL
Cancer Med; 2016 Feb; 5(2):370-85. PubMed ID: 26714930
[TBL] [Abstract][Full Text] [Related]
12. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
[TBL] [Abstract][Full Text] [Related]
14.
Huang XF; Sheu GT; Chang KF; Huang YC; Hung PH; Tsai NM
Molecules; 2020 Nov; 25(23):. PubMed ID: 33266043
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment.
Chen B; Pan Y; Xu X; Wu F; Zheng X; Chen SY; Zhao YT; Huang Z; Cheng SH; Liu JX; Wang WH; Li YX
Biomed Pharmacother; 2020 Aug; 128():110284. PubMed ID: 32480224
[TBL] [Abstract][Full Text] [Related]
16. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
17. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
18. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
Wang P; Jiang Z; Liu X; Yu K; Wang C; Li H; Zhong L
Cancer Med; 2020 Oct; 9(19):6972-6983. PubMed ID: 32779397
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway.
Zhou Q; Huang T; Jiang Z; Ge C; Chen X; Zhang L; Zhao F; Zhu M; Chen T; Cui Y; Li H; Yao M; Li J; Tian H
Oncogene; 2020 Mar; 39(10):2140-2155. PubMed ID: 31819169
[TBL] [Abstract][Full Text] [Related]
20. NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway.
Ma X; Qiu Y; Sun Y; Zhu L; Zhao Y; Li T; Lin Y; Ma D; Qin Z; Sun C; Han L
Cell Death Dis; 2020 Mar; 11(3):174. PubMed ID: 32144252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
